26.80
-0.15
(-0.56%)
At close: 1:25:49 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
43,494.00
43,494.00
188,415.00
109,822.00
22,876.00
Cost of Revenue
66,867.00
66,867.00
167,573.00
71,099.00
14,657.00
Gross Profit
-23,373.00
-23,373.00
20,842.00
38,723.00
8,219.00
Operating Expense
219,934.00
219,934.00
302,339.00
97,327.00
90,941.00
Operating Income
-243,307.00
-243,307.00
-281,497.00
-58,604.00
-82,722.00
Net Non Operating Interest Income Expense
960.00
960.00
974.00
2,168.00
1,500.00
Pretax Income
-237,690.00
-237,690.00
-267,086.00
-47,246.00
-74,453.00
Net Income Common Stockholders
-223,743.00
-223,743.00
-247,963.00
-47,246.00
-74,453.00
Diluted NI Available to Com Stockholders
-223,743.00
-223,743.00
-247,963.00
-47,246.00
-74,453.00
Basic EPS
-3.39
--
-3.87
-0.79
-1.40
Diluted EPS
-3.39
--
-3.87
-0.79
-1.40
Basic Average Shares
65,912.76
--
63,976.45
60,201.99
53,601.01
Diluted Average Shares
65,912.76
--
63,976.45
60,201.99
53,601.01
Total Expenses
286,801.00
286,801.00
469,912.00
168,426.00
105,598.00
Net Income from Continuing & Discontinued Operation
-223,743.00
-223,743.00
-247,963.00
-47,246.00
-74,453.00
Normalized Income
-223,575.00
-223,575.00
-243,044.00
-47,179.00
-74,453.00
Interest Income
1,937.00
1,937.00
1,289.00
2,393.00
1,676.00
Interest Expense
977.00
977.00
315.00
225.00
176.00
Net Interest Income
960.00
960.00
974.00
2,168.00
1,500.00
EBIT
-236,713.00
-236,713.00
-266,771.00
-47,021.00
-74,277.00
EBITDA
-228,963.00
-228,963.00
-258,424.00
-38,398.00
-67,297.00
Reconciled Cost of Revenue
66,867.00
66,867.00
167,573.00
71,099.00
14,657.00
Reconciled Depreciation
7,750.00
7,750.00
8,347.00
8,623.00
6,980.00
Net Income from Continuing Operation Net Minority Interest
-223,743.00
-223,743.00
-247,963.00
-47,246.00
-74,453.00
Total Unusual Items Excluding Goodwill
-168.00
-168.00
-4,919.00
-67.00
--
Total Unusual Items
-168.00
-168.00
-4,919.00
-67.00
--
Normalized EBITDA
-228,795.00
-228,795.00
-253,505.00
-38,331.00
-67,297.00
12/31/2020 - 9/18/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
6549.TWO TaiwanJ Pharmaceuticals Co., Ltd.
8.20
-0.12%
6709.TWO Advagene Biopharma Co., Ltd.
20.40
+0.99%
6696.TWO Lin BioScience, Inc.
130.50
+1.16%
6610.TWO TWi Biotechnology, Inc.
13.75
+0.73%
6580.TWO TaiRx, Inc.
26.10
+2.35%
6652.TWO Eusol Biotech Co.,Ltd.
7.51
-3.72%
4195.TWO Genomics BioSci & Tech. Co.,Ltd.
18.90
+2.16%
6892.TWO Taiwan Bio Therapeutics Co., Ltd
39.00
+0.13%
4178.TWO StemCyte International, Ltd.
35.00
+1.16%
4197.TWO Visgeneer Inc.
9.78
0.00%